- 专利标题: Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis
-
申请号: US15087811申请日: 2016-03-31
-
公开(公告)号: US10172866B2公开(公告)日: 2019-01-08
- 发明人: Hariprasad Vankayalapati , Venkatakrishnareddy Yerramreddy
- 申请人: Arrien Pharmaceuticals LLC
- 申请人地址: US UT Salt Lake City
- 专利权人: Arrien Pharmaceuticals LLC
- 当前专利权人: Arrien Pharmaceuticals LLC
- 当前专利权人地址: US UT Salt Lake City
- 代理机构: Foley & Lardner LLP
- 主分类号: C07D295/116
- IPC分类号: C07D295/116 ; C07D401/10 ; C07D295/135 ; C07D213/50 ; C07D211/14 ; C07D231/12 ; C07D277/42 ; C07D211/38 ; C07D211/58 ; A61K31/5375 ; C07C323/22 ; A61K31/451 ; A61K31/4545 ; A61K31/495 ; A61K31/496 ; A61K31/5377 ; A61K31/122 ; A61K31/255 ; A61K31/44 ; A61K31/445
摘要:
The present invention is directed to compounds, their synthesis, and their use as antagonists, inverse agonists, modulators and or inhibitors of the Retinoic acid-related orphan nuclear receptor γt (RORγt)/RORγ. The compounds of the present invention are useful for modulating RORγt)/RORγ activity and for treating diseases or conditions mediated by RORγt)/RORγ such as for example, disease states associated with immunopathology of human autoimmune diseases such as Multiple Sclerosis (MS), Rheumatoid Arthritis (RA), Inflammatory Colitis, Psoriasis, COPD, Pain, Obesity, Diabetes, Dyslipidemia, Osteoporosis, Asthma, Neurodegenerative diseases and Cancer.
公开/授权文献
信息查询